Soligenix Tweaks Reverse Split: Cash Now Replaces Rounding for Fractional Shares
SNGX sits 32% above its 52-week low of $0.28 on light trading volume (0.1× avg).
Summary
Soligenix amended its reverse stock split proposal to pay cash for fractional shares instead of rounding them up, a change that could cash out small stockholders and alters the tax consequences. The amendment comes as the company fights to stay listed on Nasdaq.
Key Events · Corporate Governance and Compliance · SNGX
-
Fractional Share Treatment Changed
The amendment revises the reverse stock split proposal so that stockholders entitled to a fractional share will receive a cash payment instead of having the fraction rounded up to a whole share. This could result in small holders being cashed out entirely.
-
Tax Consequences Updated
The proxy statement's discussion of U.S. federal income tax consequences has been updated to reflect the cash-in-lieu treatment, which may trigger taxable gain or loss for affected stockholders.
-
Nasdaq Delisting Risk Remains
The company received a delisting notice on June 10, 2026, and has until December 7, 2026, to regain compliance with the $1.00 minimum bid price. The reverse split is the primary tool to achieve this.
-
Authorized Share Increase Still Proposed
The proxy also seeks approval to increase authorized common shares from 75 million to 125 million, providing flexibility for future financing, partnerships, or acquisitions.
Analysis · SNGX · Life Sciences
Just two days after its initial proxy filing, Soligenix amended a key term of its proposed reverse stock split. Instead of rounding up fractional shares to the nearest whole share, stockholders who would otherwise receive a fraction will now get a cash payment. This revision could cash out many small holders entirely and changes the tax treatment for all holders. The amendment arrives as the company races to regain Nasdaq compliance by December 7, 2026—its stock trades at $0.37, well below the $1.00 minimum. The core proposals remain intact: a reverse split at a ratio between 1-for-2 and 1-for-20, and an increase in authorized shares from 75 million to 125 million, both essential for maintaining the Nasdaq listing and enabling future financing or strategic deals.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNGX was trading at $0.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.5M. The 52-week trading range was $0.28 to $6.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.